Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4238698 | Journal of Vascular and Interventional Radiology | 2012 | 4 Pages |
Abstract
Sorafenib, a protein kinase inhibitor, is a systemic drug that has been licensed for the treatment of hepatocellular carcinoma (HCC). This retrospective study assessed whether the administration of sorafenib can result in a reduction of the hepatopulmonary shunt (HPS) before selective internal radiation therapy (SIRT). After exclusion from SIRT because of high HPS, computed tomography scan indicated a shunt reduction in seven patients with HCC receiving sorafenib. Repeated measurements revealed HPS reduction (from 26.5% to 7.5% on average), and subsequent SIRT became possible. In conclusion, sorafenib may reduce HPS in patients with advanced HCC in some cases.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Jens M. MD, Jörg F. MD, Stefan MD, Judith MD, Thomas W. MD, Andreas MD, Thomas C. MD,